Medical Oncologist
Prostate cancer outcomes
Abiraterone Success Rate and Survival: — An Honest Look at the Numbers
You have just been prescribed abiraterone, or someone you love has, and you want to know whether it works. The honest answer is that it works for a proportion of patients, improves survival in the right setting, and carries real side effects worth understanding. What it does not carry is a single, reliable success rate that applies to every person.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- No single number — Abiraterone is measured in several ways — PSA response, progression-free survival, and overall survival. Each tells a different part of the story.
- Stage matters a great deal — Results vary considerably depending on whether your cancer is still hormone-sensitive or has become resistant to standard hormone therapy.
- Median is not a ceiling — When a trial reports a median survival, half the patients lived longer than that figure. It is the middle of a range, not a prediction for any individual.
- A standard-of-care treatment — NCCN and ESMO list abiraterone as a recommended option in appropriate settings. Being prescribed it means your oncologist believes you fit that profile.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Abiraterone does not have a single success rate — outcomes are measured in several ways, including PSA response, progression-free survival, and overall survival. Results vary depending on whether prostate cancer is hormone-sensitive or castration-resistant, and whether chemotherapy has been given before. NCCN and ESMO both list abiraterone as a standard option in appropriate settings.
What does 'success rate' actually mean for abiraterone?
There is no single success rate figure for abiraterone. Oncologists measure response in at least three different ways, and which one matters most depends on what your team is tracking at any given point.
PSA response measures how much the prostate-specific antigen level falls after starting treatment. Progression-free survival measures how long before the cancer starts growing again. Overall survival measures how long people live from the start of treatment.
All three appear in clinical trials and at your regular monitoring appointments. A single number quoted from a website or a well-meaning relative rarely tells the full story, because it does not say which measure was used, in which setting, or in which group of patients.
How is my response to abiraterone measured?
Regular PSA testing
Your team monitors your PSA level at each scheduled appointment. A sustained and meaningful fall in PSA is usually the earliest sign that abiraterone is working. Your team looks at the trend over several readings — a single elevated result, or a brief early rise, does not by itself mean the treatment has failed.
Symptom review at every visit
How you feel — your pain level, energy, and appetite — is part of the response picture. Symptom improvement can sometimes precede measurable changes in PSA or imaging, and worsening symptoms are a signal your team needs to hear about rather than wait for the next scan.
Testosterone level monitoring
Abiraterone works partly by suppressing testosterone production throughout the body. Your team may check your testosterone level to confirm this suppression is being maintained. If testosterone is not adequately suppressed, the drug may not be working as intended.
Imaging when your team decides it is needed
Bone scans, CT scans, and sometimes MRI or PET-CT are used to check whether visible cancer deposits have changed. Imaging is not done at every visit — your team decides when it adds useful information beyond what PSA and symptoms are already showing.
Overall assessment and treatment decision
Your oncologist combines PSA trend, symptoms, imaging, and your general health to judge whether abiraterone is still the right treatment. If it is no longer working, there are other options to discuss. If it is, continuing and monitoring is the plan.
What does a median survival figure actually mean?
When a trial reports a median overall survival, it means that half the patients in that trial lived longer than the stated figure, and half did not reach it. A median is the midpoint of a range — not an average and not an upper limit.
The range around a median can be wide. In the major abiraterone trials, some patients lived considerably longer than the median and some did not reach it. The median does not tell you which half you will be in.
Your oncologist cannot use a population median to predict your individual outcome. Your cancer's biology, the stage at which treatment started, your general health, and how well you respond to the drug all affect where on that range your experience will fall.
This is why your own PSA trend and scan results matter more to your situation than any trial statistic. Ask your oncologist what your individual markers are showing, not what the trial average was.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What do these outcome terms actually mean?
- Overall survival (OS)
- The length of time from the start of treatment until death from any cause. The outcome patients and families usually care about most, and the primary endpoint in the major abiraterone trials.
- Progression-free survival (PFS)
- The length of time from the start of treatment until the cancer starts growing again or spreads further. A useful marker of how long disease is controlled, but separate from how long someone lives overall.
- PSA response
- A meaningful fall in PSA level from its starting point, measured over successive tests. Clinical trials define this consistently; your team will tell you what trend they are watching for and how your results compare.
- Median
- The middle value in a set of results when all are lined up in order. If a trial reports a median survival, half the patients lived longer than that number and half did not reach it. Half did better.
- Castration-resistant prostate cancer (CRPC)
- Prostate cancer that continues to grow despite treatment that lowers testosterone. Abiraterone was first approved for this stage and remains a standard option within it, as listed in NCCN and ESMO guidelines.
- Hormone-sensitive prostate cancer (HSPC)
- Prostate cancer that still responds to hormone therapy. ESMO and NCCN guidance now includes abiraterone as a standard option at this earlier stage, following evidence that adding it to hormone therapy can extend survival.
What don't the survival statistics tell me about my own situation?
Can my oncologist tell me how long I have?
No oncologist can give you a reliable individual prediction, and you should be cautious of anyone who claims to. Population medians describe groups of patients, not individuals. A person who exactly matches the trial median does not exist. What your oncologist can tell you is how your own markers — your PSA trend, your imaging, your symptom trajectory — are behaving, and what that typically suggests about the path ahead. Asking 'how will we know if it is working?' is often a more useful question than 'how long do I have?'
The trial patients and I might be very different people
The major abiraterone trials enrolled patients who met specific criteria — particular fitness levels, organ function, and prior treatment histories. If you are older, have other health conditions, or have followed a different treatment path, your experience may differ from the trial population in either direction. This is not a reason to distrust the evidence; it is a reason to ask your oncologist how closely the trial population resembles your own situation, and what adjustments that might suggest.
Does a rising PSA mean abiraterone has stopped working?
Not necessarily. A brief rise in PSA shortly after starting abiraterone can sometimes occur before the level drops — a pattern oncologists have observed and accounted for in monitoring. Your team will look at whether any rise is sustained over multiple readings and whether imaging shows a corresponding change in visible disease. A single elevated reading, or a small rise over one or two tests, is rarely enough to conclude that treatment has failed. Report any change to your team and let them interpret it.
What happens when abiraterone eventually stops working?
Resistance to abiraterone develops in most patients over time. When that happens, there are other options to discuss — further hormone-based treatments, chemotherapy, or other targeted agents — depending on what you have already received and what your cancer's current biology shows. Asking now what the likely next step would be is a reasonable question, and most oncologists are glad to answer it. Knowing a plan exists makes the possibility easier to live with.
Is there anything I can do to improve my chances?
Taking abiraterone consistently as prescribed, with the steroid your team gives alongside it, is the most important thing within your control — missing doses or stopping the steroid can affect how the drug works. Attending monitoring appointments and reporting side effects early means problems are caught before they become serious. Maintaining general health through nutrition and activity within your tolerance supports your ability to stay on treatment. Whether these things extend overall survival cannot be stated with certainty, but they do affect how much benefit you get from the drug and how well you feel while receiving it.
Did you know?
Abiraterone was designed to block testosterone production not only in the testes but throughout the body, including within the tumour cells themselves.
This is why it can continue working even after standard hormone therapy has already lowered testosterone — the tumour's own ability to manufacture testosterone locally is also blocked.
Source: ESMO Clinical Practice Guidelines: Prostate Cancer
Explore 50 more Prostate Cancer Targeted Medicines topics
Drug Deep Dive: Abiraterone (Zytiga)
- Abiraterone (Zytiga, Abirapro, Abretone): The Complete Patient Guide
- Abiraterone Interactions: Steroids, BP Medicines and Herbal Products
- Abiraterone Myths: Steroids, Weight Gain and 'It Stops Working Fast'
- Abiraterone Price in India: Brand, Generic and Monthly Cost
- Abiraterone Side Effects: The Complete List and Timeline
- Abiraterone Success Rate and Survival: An Honest Look at the Numbers
- Abiraterone With ADT, Docetaxel and Radiation: Your Full Regimen Explained
- Abiraterone in Elderly Patients and Those With Other Illnesses
- Abiraterone in Hormone-Sensitive vs Castration-Resistant Prostate Cancer
- Abiraterone vs Enzalutamide: How to Choose in Prostate Cancer
- Diet and Nutrition While on Abiraterone
- Fatigue, Hot Flushes and Joint Pain on Abiraterone
- Fertility, Pregnancy and Contraception on Abiraterone
- How Does Abiraterone Work? The CYP17 Inhibitor Explained
- How Long Does Abiraterone Take to Work?
- How Long Will You Stay on Abiraterone?
- Liver Enzyme Rises on Abiraterone: Why the First Three Months Matter Most
- Swelling, Low Potassium and High Blood Pressure on Abiraterone
- Tests and Monitoring While You Are on Abiraterone
- When Abiraterone Stops Working: Resistance and What Comes Next
- Who Is Eligible for Abiraterone? Advanced and Metastatic Prostate Cancer
- Why Abiraterone Is Always Given With Prednisolone
- Why Abiraterone Must Be Taken on an Empty Stomach
- Will Insurance or a Government Scheme Pay for Abiraterone?
- Work, Travel and Daily Life on Abiraterone
Drug Deep Dive: Enzalutamide (Xtandi)
- Diet and Nutrition While on Enzalutamide
- Dizziness, Falls and Seizure Risk on Enzalutamide
- Does Enzalutamide Need a Steroid? Why It Differs From Abiraterone
- Enzalutamide (Xtandi, Bdenza, Enzamide): The Complete Patient Guide
- Enzalutamide Interactions: Blood Thinners, Statins and Seizure-Threshold Drugs
- Enzalutamide Myths: 'It's Chemotherapy', Fatigue and Loss of Masculinity
- Enzalutamide Price in India: Brand, Generic and Monthly Cost
- Enzalutamide Side Effects: The Complete List and Timeline
- Enzalutamide Success Rate and Survival: An Honest Look at the Numbers
- Enzalutamide With ADT and Other Prostate Cancer Treatments
- Enzalutamide in Elderly Patients and Those With Other Illnesses
- Enzalutamide in Non-Metastatic vs Metastatic Prostate Cancer
- Enzalutamide vs Abiraterone vs Apalutamide: Choosing an AR Inhibitor
- Fertility, Pregnancy and Contraception on Enzalutamide
- How Does Enzalutamide Work? The Androgen Receptor Signalling Inhibitor Explained
- How Long Does Enzalutamide Take to Work?
- How Long Will You Stay on Enzalutamide?
- Memory, Concentration and Blood Pressure Changes on Enzalutamide
- Severe Fatigue on Enzalutamide: The Commonest Reason Men Stop
- Taking Enzalutamide: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Enzalutamide
- When Enzalutamide Stops Working: Resistance and What Comes Next
- Who Is Eligible for Enzalutamide? Advanced and Metastatic Prostate Cancer
- Will Insurance or a Government Scheme Pay for Enzalutamide?
- Work, Travel and Daily Life on Enzalutamide
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does abiraterone work for everyone with prostate cancer?
Abiraterone is not appropriate for every person with prostate cancer, and it does not work equally in everyone it is given to. It is used in specific settings — mainly metastatic prostate cancer, whether hormone-sensitive or castration-resistant — and within those settings, some patients respond well, some partially, and some do not respond significantly. Your oncologist has recommended it because your cancer's stage and profile fit the settings where NCCN and ESMO consider it a standard option.
What percentage of patients respond to abiraterone?
Response rates vary considerably depending on whether treatment is given before or after chemotherapy, and whether the cancer is hormone-sensitive or castration-resistant. Rather than a single figure that would not describe your situation specifically, NCCN and ESMO note that abiraterone improves both progression-free and overall survival compared with control in clinical trials across multiple settings. Ask your oncologist how your cancer's profile compares with the patients who responded well in the trials that support your treatment plan.
How will I know if abiraterone is working?
The clearest early signal is your PSA trend over the first few months. A sustained and meaningful fall in PSA generally indicates the treatment is active. Your team will also track your symptoms and, when imaging is scheduled, whether visible cancer deposits have remained stable or reduced. No single measure tells the whole story — your team weighs PSA, symptoms, and imaging together. Ask them at each appointment what they are seeing, not just what the number is, so the information makes sense as it comes.
Can abiraterone be given with other treatments?
Yes. Abiraterone is always given alongside androgen deprivation therapy, because the two work together to lower testosterone more completely than either does alone. In some settings, chemotherapy is also part of the treatment plan. Abiraterone is always taken with a low-dose steroid, prescribed by your team, to prevent side effects from the drug's mechanism — never stop the steroid without checking first. Your oncologist will explain the full combination being used for your specific situation.
Is abiraterone available at CION?
Yes. Abiraterone is administered as day care at CION centres across Telangana and Andhra Pradesh. Your monitoring appointments — PSA tests, response review, and side-effect check — are built around your treatment schedule. If PET-CT or other response-assessment scans are needed, these are coordinated with partner imaging centres. Speak to your care team about which centre is most convenient and what your appointment schedule will look like.
What should I ask my oncologist about my expected outcomes?
Three questions are worth asking directly: What are you monitoring, and what would a good result look like in the first few months? What is the plan if this treatment stops working? And how does my cancer profile compare with the patients who responded well in the trials? Writing down the answers helps — these conversations are difficult to remember when you are worried. Asking about your specific markers rather than population statistics will give you more useful information than any figure from a website.